Back to Search
Start Over
Cognitive phenotyping of GBA1-Parkinson's disease: A study on deep brain stimulation outcomes.
- Source :
-
Parkinsonism & related disorders [Parkinsonism Relat Disord] 2024 Nov; Vol. 128, pp. 107127. Date of Electronic Publication: 2024 Sep 17. - Publication Year :
- 2024
-
Abstract
- Background: Heterozygous variants in the glucocerebrosidase (GBA1) gene are the most common genetic risk factor for Parkinson's Disease (PD). GBA1-PD patients exhibit earlier disease onset, severe motor impairment, and heightened cognitive decline. Deep Brain Stimulation (DBS) offers motor improvement for PD patients, but its cognitive effects, particularly in GBA1-PD, are debated.<br />Methods: This study involved 96 PD patients who underwent subthalamic nucleus DBS at Hospital de la Santa Creu i Sant Pau between 2004 and 2023. Clinical and neuropsychological assessments were conducted pre- and post-surgery, focusing on Mattis Dementia Rating Scale (MDRS) and Frontal Systems Behavior Scale (FrSBe). Patients were categorized into GBA1-PD and non-GBA1-PD groups, with non-GBA1-PD further divided into cognitive fast-progressors and slow-progressors.<br />Results: GBA1 variants were present in 13.5 % of patients. GBA1-PD patients showed greater cognitive decline over time, particularly in attention, conceptualization, and memory, compared to non-GBA1-PD. Non-GBA1-PD fast-progressors exhibited significant cognitive deterioration in initiation and conceptualization within the first year post-DBS. Motor outcomes improved similarly across all groups, but slow-progressors showed a greater reduction in Levodopa Equivalent Daily Dose (LEDD).<br />Conclusions: GBA1-PD patients experience more rapid cognitive decline, particularly in posterior-cortical and fronto-striatal functions. Additionally, a subset of non-GBA1-PD patients shows significant early cognitive decline post-DBS, especially in executive functions. Baseline MDRS scores do not predict cognitive outcomes, highlighting the need for further research to refine prognostic tools. Despite cognitive challenges, GBA1-PD patients benefit from DBS in terms of motor outcomes, underscoring the importance of individualized assessments for DBS suitability, regardless of genetic status.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Subjects :
- Humans
Female
Male
Middle Aged
Aged
Subthalamic Nucleus
Treatment Outcome
Disease Progression
Glucosylceramidase genetics
Deep Brain Stimulation
Parkinson Disease therapy
Parkinson Disease genetics
Parkinson Disease complications
Cognitive Dysfunction etiology
Cognitive Dysfunction therapy
Cognitive Dysfunction physiopathology
Phenotype
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5126
- Volume :
- 128
- Database :
- MEDLINE
- Journal :
- Parkinsonism & related disorders
- Publication Type :
- Academic Journal
- Accession number :
- 39357432
- Full Text :
- https://doi.org/10.1016/j.parkreldis.2024.107127